Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics Inc (VRDN) is a clinical-stage biopharmaceutical company pioneering targeted therapies for thyroid eye disease through its novel IGF-1R inhibitor Veligrotug. This page serves as the definitive source for verified updates on clinical trials, regulatory milestones, and corporate developments.
Investors and medical professionals will find timely updates on:
• Phase 3 trial progress for subcutaneous and intravenous formulations
• FDA communications and regulatory pathway updates
• Strategic partnerships enhancing drug development
• Financial disclosures and earnings call summaries
All content is sourced directly from company filings and official press releases, ensuring reliability for investment research and clinical practice decisions. Bookmark this page for streamlined access to VRDN's latest advancements in monoclonal antibody therapeutics.
Viridian Therapeutics, Inc. announced the approval of non-qualified stock options for six new employees. The Inducement Grants were granted outside of the company's Equity Incentive Plan but are subject to its terms. The grants aim to attract new talent and were approved by independent directors. The options have an exercise price equal to the closing price of the company's common stock on the Grant Date and will vest over a four-year period.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will host a webcast to discuss its first quarter 2024 financial results and recent business highlights on May 8, 2024. The company focuses on discovering medicines for serious and rare diseases.
FAQ
What is the current stock price of Viridian Therapeutics (VRDN)?
What is the market cap of Viridian Therapeutics (VRDN)?
